ERYTECH Pharma S.A. (NASDAQ:ERYP – Get Free Report)’s stock price was down 4.5% during trading on Friday . The stock traded as low as $0.49 and last traded at $0.51. Approximately 12,777 shares traded hands during trading, a decline of 86% from the average daily volume of 93,510 shares. The stock had previously closed at $0.53.
ERYTECH Pharma Price Performance
The company has a quick ratio of 3.65, a current ratio of 3.65 and a debt-to-equity ratio of 0.32. The business’s 50-day moving average is $0.62 and its two-hundred day moving average is $0.78.
Institutional Inflows and Outflows
An institutional investor recently bought a new position in ERYTECH Pharma stock. Vanguard Personalized Indexing Management LLC bought a new position in shares of ERYTECH Pharma S.A. (NASDAQ:ERYP – Free Report) during the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm bought 95,268 shares of the company’s stock, valued at approximately $107,000. Vanguard Personalized Indexing Management LLC owned about 0.31% of ERYTECH Pharma at the end of the most recent quarter. 1.09% of the stock is owned by institutional investors.
ERYTECH Pharma Company Profile
ERYTECH Pharma SA, a biopharmaceutical company, focus on development of red blood cell-based therapeutics for cancer and orphan diseases in France and the United States. It develops eryaspase, which is in Phase 3 clinical development for the treatment of second-line pancreatic cancer, and in Phase 2 stage for the treatment of triple-negative breast cancer and second-line acute lymphoblastic leukemia patients.
- Five stocks we like better than ERYTECH Pharma
- Industrial Products Stocks Investing
- MarketBeat Week in Review – 8/28 – 9/1
- The How and Why of Investing in Large-Cap Stocks
- 2 Stocks That Doubled EPS Estimates and Flashing Buy Signals
- How to Use High Beta Stocks to Maximize Your Investing Profits
- Toyota vs Tesla: The Tortoise And The Hare Race Has A New Meaning
Receive News & Ratings for ERYTECH Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ERYTECH Pharma and related companies with MarketBeat.com's FREE daily email newsletter.